Sotac Pharmaceuticals Ltd
Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]
- Market Cap ₹ 119 Cr.
- Current Price ₹ 108
- High / Low ₹ 152 / 100
- Stock P/E 23.9
- Book Value ₹ 50.1
- Dividend Yield 0.09 %
- ROCE 11.4 %
- ROE 9.40 %
- Face Value ₹ 10.0
Pros
Cons
- Debtor days have increased from 112 to 144 days.
- Working capital days have increased from 95.7 days to 164 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 23.41 | 28.68 | 43.44 | 73.15 | 57.98 | 67.11 | 62.38 | 56.57 | |
| 21.46 | 26.70 | 40.58 | 65.13 | 49.73 | 56.91 | 54.70 | 48.25 | |
| Operating Profit | 1.95 | 1.98 | 2.86 | 8.02 | 8.25 | 10.20 | 7.68 | 8.32 |
| OPM % | 8.33% | 6.90% | 6.58% | 10.96% | 14.23% | 15.20% | 12.31% | 14.71% |
| 0.34 | 0.69 | 0.35 | -1.63 | 0.24 | 1.09 | 2.38 | 2.55 | |
| Interest | 0.49 | 0.37 | 0.61 | 0.58 | 0.90 | 1.02 | 1.17 | 1.68 |
| Depreciation | 1.04 | 1.07 | 1.11 | 1.13 | 1.63 | 2.51 | 2.47 | 2.48 |
| Profit before tax | 0.76 | 1.23 | 1.49 | 4.68 | 5.96 | 7.76 | 6.42 | 6.71 |
| Tax % | 0.00% | 0.00% | 0.00% | 29.91% | 24.66% | 25.90% | 25.55% | |
| 0.76 | 1.23 | 1.48 | 3.30 | 4.50 | 5.75 | 4.77 | 4.99 | |
| EPS in Rs | 8.00 | 5.35 | 6.43 | 14.35 | 5.59 | 5.20 | 4.32 | 4.52 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 13.94% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | -5% |
| TTM: | -12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 1% |
| TTM: | -3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 15% |
| Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.95 | 2.30 | 2.30 | 2.30 | 8.05 | 11.05 | 11.05 | 11.05 |
| Reserves | -0.04 | 1.40 | 2.51 | 4.80 | 12.94 | 37.22 | 41.98 | 44.30 |
| 8.11 | 7.24 | 6.68 | 7.39 | 10.66 | 11.17 | 20.13 | 15.89 | |
| 7.45 | 10.43 | 11.01 | 21.82 | 23.13 | 16.64 | 12.13 | 14.73 | |
| Total Liabilities | 16.47 | 21.37 | 22.50 | 36.31 | 54.78 | 76.08 | 85.29 | 85.97 |
| 7.54 | 6.41 | 6.42 | 8.80 | 14.09 | 17.67 | 16.66 | 16.16 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.20 | 0.81 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 11.50 | 13.33 | 12.23 |
| 8.93 | 14.96 | 16.08 | 27.51 | 36.65 | 46.86 | 55.10 | 56.77 | |
| Total Assets | 16.47 | 21.37 | 22.50 | 36.31 | 54.78 | 76.08 | 85.29 | 85.97 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 2.22 | 3.58 | 8.54 | -19.75 | -6.08 | |||
| -1.07 | -3.28 | -10.93 | -12.53 | -1.89 | |||
| -1.17 | -0.30 | 11.97 | 23.32 | 7.78 | |||
| Net Cash Flow | -0.02 | 0.00 | 9.57 | -8.96 | -0.20 | ||
| Free Cash Flow | 1.09 | 0.08 | 1.58 | -25.85 | -7.71 | ||
| CFO/OP | 26% | 62% | 124% | -177% | -69% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 72.81 | 107.92 | 52.68 | 62.57 | 72.40 | 119.71 | 144.41 |
| Inventory Days | 42.90 | 39.50 | 40.71 | 35.14 | 87.26 | 88.99 | 84.58 |
| Days Payable | 140.53 | 175.52 | 112.49 | 128.97 | 165.78 | 119.11 | 77.52 |
| Cash Conversion Cycle | -24.81 | -28.10 | -19.10 | -31.25 | -6.12 | 89.59 | 151.47 |
| Working Capital Days | 6.08 | 31.05 | 26.89 | -2.94 | -0.63 | 124.11 | 163.60 |
| ROCE % | 15.53% | 18.72% | 54.66% | 29.74% | 19.78% | 11.43% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Export Market Reach Countries |
|
||
| Installed Capacity - Capsules (Sotac Pharma) Crore per year |
|||
| Installed Capacity - Tablets (Sotac Healthcare) Crore per year |
|||
| Installed Capacity - Tablets (Sotac Pharma - Standalone) Crore per year |
|||
| Number of Corporate Clients Number |
|||
| R&D Scientists Number |
|||
| Total Full-time Employees Number |
|||
| Manufacturing Permissions - Sotac Pharma Number of Products |
|||
| Products sold in US Market Number |
|||
Documents
Announcements
-
Trading Window
30 March 2026 - Trading window closed April 1, 2026 until 48 hours after FY/HY results for March 31, 2026.
-
Appointment
27 March 2026 - Mar 27, 2026: Appointed Mittal V. Kothari (secretarial) and GBP & Associates (internal) auditors for FY2025-26.
-
Appointment
27 March 2026 - Appointed Mittal V. Kothari (Secretarial Auditor) and GBP & Associates (Internal Auditor) on March 27, 2026.
-
Outcome of Board Meeting
27 March 2026 - Board appointed secretarial auditor Mittal V Kothari and internal auditor GBP & Associates for FY2025-26 on March 27, 2026.
-
Bagging/Receiving of orders/contracts
25 February 2026 - Intas order of Rs.48,76,300 for Entacom 10/Entacom Plus; supplies Mar 11–May 11, 2026.
Business Overview:[1]
SPL specializes in manufacturing a broad range of pharmaceutical products across various therapeutic areas, including anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological treatments, antacids, anti-ulcer (PPI), anti-emetics, cardiac, antihypertensives, analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral, general antibiotics (β-lactams and non-β-lactams), antifungal, and cephalosporins.